Centre Hospitalier De Perigueux
- Address
- lock Available on a paid plan
Virus Diseases and Chronic Hepatitis D
At Centre Hospitalier De Perigueux, research in infectious disease focuses on virus diseases, especially chronic hepatitis D infection. The trial work is aimed at understanding whether a new treatment approach can help slow liver disease progression and reduce liver-related complications over time.
- Evaluating treatment effectiveness in chronic hepatitis D
- Tracking long-term liver disease outcomes
- Assessing prevention of liver-related events
This area reflects a strong interest in improving care for persistent viral infection and its impact on long-term health.
Respiratory Tract Diseases and Community-Acquired Pneumonia
Clinical research also covers respiratory tract diseases, with a focus on community-acquired pneumonia in older adults. The study is designed to compare common antibiotic approaches and determine whether a narrower treatment strategy can perform as well as broader therapy in routine hospital care.
- Comparing antibiotic strategies for community-acquired pneumonia
- Studying treatment effectiveness in patients aged 65 years or older
- Supporting better antimicrobial therapy choices
This work highlights practical research aimed at improving everyday treatment decisions for hospitalized patients with pneumonia.
Bacterial Infections and Mycoses in Hospital Care
The site’s trial portfolio also includes research in bacterial infections, reflecting broader efforts to refine infection management in a hospital setting. These studies look at whether targeted treatment choices can maintain clinical effectiveness while supporting more appropriate use of antibiotics.
- Evaluating care for bacterial infections
- Testing the effectiveness of narrower versus broader antimicrobial approaches
- Improving infection treatment in hospitalized patients
Overall, the research emphasizes better-informed treatment selection for common infectious diseases treated at this hospital.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 137 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 134 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Perigueux
lock Showing 1 of 30 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III Double-Blind, Placebo-Controlled Study of Adjuvant Durvalumab in Resected Stage IB-IIIA Non-Small Cell Lung Cancer with PD-L1 Expression ≥25% | Clinipace Global Limited, Fundacion GECP, Intergroupe Francophone De Cancerologie Thoracique, NVALT-studies Stichting, Queen's University | Phase III | Not Recruiting | Mar 2015 | Mar 2025 |
IMP list
lock Showing 1 of 137 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 7 | Unknown | 2019-04-25 | 2025-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.